ArticleCellular oncology (Dordrecht, Netherlands)2024

Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis.

Yifei Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.